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Abstract. Subthalamic Nucleus Deep Brain Stimulation (STN DBS) is a well-established and effective treatment modality for
selected patients with Parkinson’s disease (PD). Since its advent, systematic exploration of the effect of stimulation parameters
including the stimulation intensity, frequency, and pulse width have been carried out to establish optimal therapeutic ranges.
This review examines published data on these stimulation parameters in terms of efficacy of treatment and adverse effects.
Altering stimulation intensity is the mainstay of titration in DBS programming via alterations in voltage or current settings,
and is characterised by a lower efficacy threshold and a higher side effect threshold which define the therapeutic window.
In addition, much work has been done in exploring the effects of frequency modulation, which may help patients with gait
freezing and other axial symptoms. However, there is a paucity of data on the use of ultra-short pulse width settings which
are now possible with technological advances. We also discuss current evidence for the use of novel programming techniques
including directional and adaptive stimulation, and highlight areas for future research.
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INTRODUCTION
Deep brain stimulation (DBS) of the subthala-
mic nucleus (STN) has been well established as
an effective treatment option for selected patients
with Parkinson’s disease (PD) since its use was first
demonstrated in humans over two decades ago [1–3].
Systematic exploration of electrical parameters and
their various effects was carried out in the early era
of DBS being made widely available, and included
examining the effects of altering stimulation inten-
sity, frequency, and pulse-width (PW) [4, 5]. There
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has since been further work on alternative parameter
settings, largely focusing on the effects of modulating
frequency values [6–14].
In recent years, in addition to these stimulation
parameters, novel programming techniques along
with advances in technology have enabled more
selective spatial control of stimulation current with
directional steering, and the use of feedback signals
to continuously and automatically adjust delivery of
current as required with closed-loop adaptive stimu-
lation methods [15–22].
Here, we review the published data to date on the
effects of variation of electrical stimulation parame-
ters including amplitude, frequency, and pulse width
as it applies to subthalamic DBS in Parkinson’s
disease, as well as newer programming techniques
of directional and adaptive stimulation.
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METHODS
A structured Pubmed search was performed
through August 2016 with search terms “Subthala-
mic Deep Brain Stimulation in Parkinson’s Disease”,
“voltage”, “current”, “frequency”, “pulse width” and
“side effects”. We reviewed case series, observa-
tional studies, and controlled trials that examined the
clinical effect of quantitatively varying one or more
stimulation parameters on symptoms of Parkinson’s
disease, and on the occurrence of adverse effects.
For novel programming techniques, we combined
the first search term with “adaptive” and “direc-
tional” respectively, and included interventional or
descriptive case reports, case series and controlled
trials that compared these techniques to conventional
DBS. Only articles focusing on subthalamic stim-
ulation in Parkinson’s disease and in English were
included.
THE EFFECT OF VARYING
PARAMETERS
Any positive or negative effect emerging as a result
in a change in the stimulation parameters delivered
through a DBS contact will depend entirely on the
precise location of that contact in the brain. Given
the natural anatomical variation between patients,
as well as variations in surgical technique, targeting
and precision, there is inevitably a confounding fac-
tor in the interpretation of stimulation adjustments
between patients. Nevertheless, important lessons
can be learned by systematic study of large numbers
of patients, and the data emerging from such studies
is presented below.
Stimulation intensity
The stimulation intensity has the greatest effect
on ameliorating Parkinsonian motor signs relative to
energy-equivalent changes in other parameters, and
is the most commonly titrated parameter in the ini-
tial stages of subthalamic DBS programming. This
can be done by controlling the voltage or the cur-
rent, which are interrelated by the impedance factor.
Implantable pulse generators (IPGs) programmed to
use constant voltage (CV) titration control the max-
imum voltage associated with each pulse, while the
current will vary depending on the impedance. Con-
versely, programming using constant current (CC)
provides a specified electrical current while adjusting
the voltage to compensate for the impedance [23].
In-vitro studies of constant current stimulation
have demonstrated the current waveform to be more
uniform in terms of intensity, exhibiting less decay
than in constant-voltage stimulation. However, com-
parisons of CC and CV stimulation to achieve
equivalent motor efficacy have not shown any signif-
icant differences in non-motor outcomes, including
cognition, mood, and quality of life in a double-blind
crossover trial [23]. A retrospective analysis of 19
patients with PD and dystonic syndromes switched
from CV to CC stimulation reported no change in
measured clinical outcomes and therapy satisfaction
at 6 months [24].
Rizzone et al. carried out early systematic explo-
ration of the impact of various parameter settings
in STN DBS in a double-blinded evaluation of 10
patients. They examined the relationship of stimu-
lus intensity in terms of current and the occurrence
of therapeutic as well as adverse effects at various
frequency and pulse-width settings. The intensity
required to produce the clinical effect of loss of wrist
rigidity ranged from 0.7 to 1.7 mA, and the intensity
required to produce adverse effects ranged from 1.3
to 3.4 mA [4]. The relationships between the stim-
ulus intensity required to produce these effects and
frequency as well as pulse-width are discussed in the
corresponding sections below.
Subsequently, in a double blinded assessment of 12
patients, Moro and colleagues found that the mean
highest tolerated voltage was 3.5 V, while keeping
frequency constant between 130–185 Hz and PW
constant between 60–90 s [5]. Bradykinesia and
rigidity significantly improved at 2 V and 3 V with
testing carried out at 1 V intervals, while response to
tremor was seen starting at 1 V, with 2 V and 3 V being
progressively more effective. The greatest beneficial
effect on these segmental motor signs was noted to be
at 3 V, with no significant additive benefit at voltage
settings above this.
Voltage-dependent side effects commonly con-
sist of motor or sensory symptoms, occurring in
the majority with progressive increase in voltage.
Anatomically, these effects are thought to represent
current spread to the pyramidal tract, causing muscle
contractions, and the medial lemniscus, resulting in
paraesthesias. Autonomic effects may include exces-
sive sweating, flushing, mydriasis, tachycardia, and
a sensation of heat or cold. In an intraoperative
investigation of clinical effects produced by STN
stimulation in 17 PD patients, Sauleau et al. found
that using 130 Hz and 100 s settings, the thresh-
old for complete disappearance of wrist rigidity was
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0.94 V. The mean adverse effect thresholds were:
2 V for paraesthesias, 3 V for oculomotor effects,
3.1 V for autonomic effects, and 3.4 V for dystonic
effects [25].
Tommasi et al. investigated pyramidal side effects
of subthalamic stimulation by progressively increas-
ing voltages through chronically used contacts while
keeping PW and frequency constant at 60 s and
130 Hz respectively. Motor side effects were the
most frequent, seen in 27 out of 28 electrodes, fol-
lowed by sensory symptoms in 23. The most frequent
adverse effects included contractions involving the
facial muscles, often affecting bilateral upper facial
and contralateral lower facial muscles. Dysarthria
was observed in about 25% of subjects. Oculomo-
tor side effects were seen in 6 out of 28 electrodes
tested, and most commonly consisted of reduced gaze
ipsilateral to stimulation, progressing to contralateral
gaze deviation with increasing voltage. The median
voltage required to produce oculomotor effects was
5.5 V, as compared to 4.5 V for sensory symptoms.
Nausea and excessive sweating also occurred in 6
electrodes. Non-specific effects were common and
nearly half of subjects experienced symptoms such as
dizziness, a sense of heavy-headedness or lighthead-
edness, feeling of an electric current through the body,
or malaise. They noted that habituation to sensory,
oculomotor, and autonomic effects such as nausea
and excessive sweating occurred rapidly as opposed
to pyramidal tract side effects which tended to be per-
sistent. No affective or behavioural effects related to
stimulation were noted [26].
Eyelid opening apraxia has also been observed, and
has been shown to have a mean threshold of occur-
rence of 5.2 v, although this symptom may be present
as part of PD itself, and is occasionally relieved by
stimulation [2, 26–28]. As well as these, stimulation-
induced dyskinesias were observed in 5 of 12 patients,
and foot dystonia in one of these [5].
In addition to voltage dependent adverse effects
discussed, progressively increasing voltage (median
5.5 v) at the standard frequency of 130 Hz has been
shown to worsen gait and increase freezing episodes,
similar to the condition off-stimulation [6]. Speech
intelligibility and articulation are also impaired with
increasing amplitude, particularly above 3.5 V [29],
and a stronger correlation with high voltages in the
left STN and speech impairment has been observed
[26, 30, 31]. Stimulation related psychiatric effects
such as mania are also widely recognised, and
attributed to involvement of limbic structures from
stimulation of anteromedial neurons in the STN.
These often respond to either a reduction in stimu-
lation intensity or shifting to using more dorsolateral
electrode contacts [32, 33].
While quantitative data on time to habituation of
adverse effects is limited, in the authors’ experience,
sensory and autonomic effects tend to subside within
seconds if the stimulation intensity is maintained at
the threshold level at which these occur. Time to
habituation of capsular effects has not been explored
as they are not well-tolerated.
Frequency
The use of frequencies of less than 50 Hz in
subthalamic stimulation has been shown not to
have a clinically significant effect on measurable
motor signs in Parkinson’s disease, even when com-
bined with higher compensatory values of stimulus
intensity and pulse-width [4]. In fact, very low fre-
quencies of 5–10 Hz have been found to worsen
motor symptoms, particularly bradykinesia, com-
pared with no stimulation [5, 34, 35]. Moro et
al. noted that all frequencies over 50 Hz signif-
icantly improved bradykinesia and tremor, while
the threshold for response in terms of rigidity was
33 Hz. The ceiling of beneficial effect was in the
range of 130–185 Hz, with progressive improvement
in cardinal motor signs with increasing frequency
which was significant between 50 Hz and 130 Hz
but not between 130 Hz and 185 Hz or 250 Hz
[5]. Observations have been made of requiring a
lower stimulus intensity to achieve the same clinical
effect with increasing frequencies between 90 and
170 Hz, but this was not significant in a study of 10
patients [4].
Adverse effects of stimulation seem to vary
depending on frequency settings: effects produced
at lower frequencies (<50 Hz) include worsening of
tremor and myoclonic jerks as opposed to paraesthe-
sias, muscle contractions and dyskinesias at higher
frequencies (90–170 Hz). At a given stimulus inten-
sity, a trend to a lower side effect threshold was
observed with progressively higher frequency set-
tings, from 90 Hz to 170 Hz [4, 5]. Higher rates of
185 Hz and 250 Hz produced lower limb dyskinesias
in one of 12 patients, and a subjective sensation of a
heavy head in two of these [5].
In contrast to the good response seen in allevi-
ation of segmental motor signs of PD with STN
stimulation, gait dysfunction and other axial symp-
toms can evolve to become relatively refractory to
conventional programming settings. High frequency
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stimulation at conventional settings of 130 Hz com-
bined with high voltage has even been associated
with increased incidence of gait freezing [6, 36]. This
has led to multiple studies investigating the effect
of alternative frequency settings on gait. In a ran-
domised blinded assessment, Moreau et al. examined
13 patients with severe gait disorders on frequency
settings of 60 Hz and 130 Hz, with voltages adjusted
so that the total energy delivered was constant. While
there was no significant difference in UPDRS gait
and axial subscores, 60 Hz stimulation resulted in a
significantly lower number of freezing episodes and
reduction in number of steps on a Stand-Walk-Sit
(SWS) test. The clinical benefit on gait persisted at 8
months follow up in 85% of patients, although they
were noted to be on higher doses of levodopa at this
time [6].
A randomised trial of 14 patients with double-
blind crossover design comparing 60 Hz and
130 Hz energy-equivalent stimulation found similar
improvements in axial symptoms and akinesia with
the lower frequency setting when assessed at one
hour, with no significant differences in segmental
signs between the two settings. Significant reductions
in total UPDRS-III as well as axial and akinesia sub-
scores, and a timed 10-metre walk test were noted
with the lower frequency setting. Also of note in
this study is that for 5 patients the optimal contact
positions for low frequency stimulation were more
ventrally located in the subthalamic nucleus than opti-
mal contacts for 130 Hz stimulation [9].
In a case series, Xie et al. described two patients
with acute worsening of freezing of gait (FOG) at
standard frequency subthalamic stimulation (130 Hz)
following new activation of their DBS systems.
These demonstrated the immediate negative effect of
high frequency stimulation as distinct from chronic
adverse effects and those of disease progression,
which complement findings in patients who have had
stimulation for longer periods. They reported ame-
lioration of FOG with 60 Hz stimulation and initially
unchanged amplitude and pulse width settings. The
effect persisted at a 10 month follow up, and was
present in both ON and OFF medication states. In
addition to FOG, there was noted to be improve-
ment in bradykinesia and other axial symptoms with
low frequency stimulation [36]. Subsequently, this
effect on axial symptoms was reproduced with 60 Hz
stimulation in a small randomised double-blind trial,
including improvement in dysphagia and aspiration
frequency specifically, quantified as a 57% reduction
on a modified barium swallow assessment [10].
Another case series reported that in patients with
dopa-responsive axial and gait dysfunction that ini-
tially worsened with high frequency stimulation
(130–185 Hz), there was subsequent improvement
with 60 Hz stimulation in four out of five patients.
Immediate worsening of gait and freezing was also
demonstrated on experimental switching of settings
back to high frequency. Ventral contacts were used
in all patients, and double monopolar configuration
involving concomitant dorsal and ventral contacts
was utilised in three patients due to observed benefi-
cial effects on gait and reduction in dyskinesias [11].
However, the evidence for low frequency stimu-
lation being beneficial for axial symptoms of PD is
not unequivocal. The largest reported cohort studied
involved 45 patients with refractory axial symptoms
on high frequency (130 Hz) stimulation who were
switched to 80 Hz settings in an open label trial,
and showed no significant change in total motor
UPDRS and axial and gait subscores at a median
assessment period of 112 days [7]. In addition, in
a randomised trial of 20 patients with gait difficul-
ties following STN stimulation, Phibbs et al. did
not find any improvement in stride length or num-
ber of freezing episodes with switching from 130 Hz
to 60 Hz. However, notably, other parameters in this
study including the stimulation intensity were kept
constant at both frequency settings, resulting in a
lower total electrical energy delivered (TEED) value
at low frequency [8].
Furthermore, despite the majority of studies on
the utility of low frequency stimulation showing
initial improvement in gait and freezing with low
frequency stimulation in the range of 60–80 Hz [6,
9–11, 36], it is possible that these effects may not be
sustained over time. An open label trial involving 11
patients found that despite initial improvements in
gait as measured by performance on the SWS test
after switching from 130 Hz to 80 Hz at equivalent
energy delivered, the benefit was not maintained at
1, 5 and 15 months. Reduction in freezing episodes
was also short-lived, being sustained at one month
but not subsequently [12].
In an open label prospective analysis, Brozova et al.
found mixed results with low frequency stimulation
among 12 patients with gait dysfunction and postu-
ral instability; three could not tolerate low frequency
due to worsening of segmental symptoms, two had
worsening of postural stability and gait, while seven
benefited [13].
In addition, although most studies have reported no
significant change in control of segmental symptoms
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as measured by UPDRS with low frequency stim-
ulation, it has been observed that tremor control is
often worse than at standard high frequencies [10, 12,
36]. Low frequency stimulation also may not produce
beneficial effects over conventional higher frequency
settings in patients who do not suffer from problems
with gait and postural control [14].
Pulse width
Pulse width values available for use in subthalamic
stimulation in PD have conventionally ranged from
60 s to 450 s. Increasing pulse width values up to
a certain level has been shown to require correspond-
ingly lower stimulus intensities to achieve a required
clinical effect. This relationship was observed by Riz-
zone et al. between a low pulse width of 60 s and
higher values of 210 s or 450 s, but not between
these higher pulse width parameters, where the effect
seems to plateau. A parallel relationship exists with
the occurrence of adverse effects at increasing pulse
widths: i.e. a lower stimulus intensity is required
to produce adverse effects at higher pulse width
values. This results in a narrower therapeutic win-
dow (magnitude of difference in the intensity value
required to produce a clinical effect and that required
to produce adverse effects) with increasing pulse
widths [4].
Similarly, Moro et al. found that of the 12 patients
studied, 5 were unable to tolerate PWs of greater
than 210 s when combined with a voltage of 75%
of the usual chronic stimulation setting. The mean
highest tolerated level was 190 s in this group.
Adverse effects that limited use of higher PW val-
ues were similar to those produced by increasing
stimulation intensity; muscle contractions, paraesthe-
sias, dysarthria and postural tremor were commonly
observed. Improvement in tremor control and rigid-
ity was observed at all PWs studied between 60 s
and 210s, while reduction in bradykinesia was only
significant at 60 s relative to baseline [5].
There has been limited further exploration of the
effects of pulse width in STN DBS beyond the pio-
neering data available from the work of Rizzone and
Moro discussed. However, more recently, interest in
the effects of PWs shorter than the conventional lower
limit of 60 s has emerged, as this has now become
possible with advances in DBS equipment.
Reich et al. recently reported their findings on the
use of PWs of less than 60 s at a fixed frequency
of 130 Hz in a monopolar review session of four
patients. An inverse relationship between PW and
therapeutic window was noted in all subjects, with
therapeutic window (TW) being defined as the dif-
ference in the minimum stimulation current required
to produce adverse effects and that required to pro-
duce the clinical effect of loss of rigidity (efficacy
threshold). Compared to standard 60 s stimulation,
the TW increased by a mean of 182% with a PW of
30 s, and decreased by 46% with a PW of 120 s.
TWs could not be obtained at lower PWs of 20 s
due to a lack of capsular response using a predefined
maximum of 10 mA stimulation intensity. The cor-
responding stimulation current required for rigidity
control increased with reducing PWs, from a mean
of 1.6 mA at 60 s to 2.9 mA at 30 s. Furthermore,
the authors noted that while this efficacy threshold
in mA increased at lower PWs, the total charge per
pulse required for the clinical effect of rigidity control
decreased. They postulated short PW may therefore
potentially prolong IPG battery life [37].
Table 1 summarises the findings of studies dis-
cussed above examining the effects of varying
different stimulation parameters.
Directional steering
Directional stimulation involves using segmented
or multi-contact electrodes which replace con-
ventional cylindrical electrodes, so that selective
activation of one or more contacts can be used to pro-
duce a field of stimulation in the desired orientation
to more selectively target adjacent neural tissue.
Intra-operative proof of concept studies to explore
hypotheses that directional steering of current would
result in more efficient stimulation and a reduction in
adverse effects have been carried out in the last 2-3
years [15–17]. The first of these showed that using a
specially designed lead with six directional contacts
(3 each on 2 horizontal levels), the widest therapeutic
window obtained with directional stimulation was on
average 41% larger than with omnidirectional stim-
ulation which simulated a conventional ring-shaped
electrode. The therapeutic window could be increased
in 10 of 11 patients compared to using omnidirec-
tional stimulation. In addition to this, the average
current threshold for therapeutic effect was noted
to be 43% lower with best directional stimulation
[15].
A similar intraoperative study used 32-contact
electrodes to compare directional stimulation in four
steering modes to conventional spherical stimulation
in a double-blinded assessment of 8 patients with
Parkinson’s disease. For 13 of the 15 side effects
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induced by conventional stimulation, steering in at
least one direction led to an increase in the thresh-
old for producing these by at least 1 mA. The TW
was evaluated with respect to improvement in rigid-
ity as the therapeutic effect in 3 patients; all of whom
demonstrated an increase of between 0.5 and 2.5 mA
with directional stimulation [16].
Following the results of intraoperative studies,
Steigerwald et al. reported their clinical experience
with implantation of the CE marked Vercise PC
(Boston scientific™) directional system with multi-
ple independent current source control (MICC) in 7
patients with PD. A post-operative monopolar review
session was used to determine thresholds for thera-
peutic and adverse effects, and expansion in the TW
with directional modulation seen in previous experi-
mental studies was confirmed at 17 of 22 stimulation
sites. This study was designed to demonstrate feasi-
bility rather than efficacy, and at a median of 4 months
follow up, all patients remained on directional stimu-
lation without needing to switch to conventional ring
mode stimulation [18].
As expected, the direction of stimulation generally
correlates with adverse effects produced by activation
of known fibre tracts at those locations, with lat-
eral stimulation producing the most common adverse
effects of focal muscle contraction and dysarthria
from corticospinal tract activation [15, 16, 18].
Adaptive stimulation
The concept of adaptive stimulation broadly
involves a means of obtaining feedback on patho-
logical brain activity and responding with varying
stimulation accordingly. This has been studied with
closed-loop systems which record local field poten-
tials (LFPs) via stimulation electrodes, and in
particular using beta frequency (13–35 Hz) activity
in the STN which has been shown to correlate with
the degree of motor impairment in PD [21, 38–42].
Little et al. first demonstrated the utility of this
approach systematically in patients with PD in 2013.
Data was collected on eight patients with unilateral
STN stimulation, and they reported that compared
to the unstimulated state, there was a mean reduc-
tion of 50% in UPDRS motor scores on blinded
assessments with the adaptive approach compared
to 31% with continuous stimulation. Not only was
there more effective overall control of motor symp-
toms, but adaptive DBS seemed to have less than half
the energy requirements of continuous stimulation by
virtue of its intermittent nature [19].
This was studied again by these authors with
bilateral stimulation, with independent sensing and
activation on each side according to the amplitude
of beta activity at the electrode. Although there was
no direct comparison with continuous DBS, UPDRS
motor scores were 43% better relative to no stimu-
lation, despite stimulation being on for only 45% of
the time, and resulting in an energy saving similar
to that found in the first study. In addition to this,
adaptive DBS seemed to have a synergistic effect
with Levodopa on Parkinsonian motor signs, with an
appropriate reduction in stimulation in response to
reduced beta activity and clinical improvement which
temporally corresponded with the action of Levodopa
after its administration [20].
However, despite the encouraging findings of
adaptive DBS use in the early post-operative period,
as yet data is restricted to limited testing over
short time periods only. There has been one case
report of the beneficial effects of adaptive DBS in
a freely mobile patient being maintained at day 6
post-operatively with a testing period of 2 hours.
The patient was found to have stable control of
segmental symptoms without dyskinesias, and also
demonstrated similar improvement in axial symp-
toms compared to conventional continuous DBS [22].
Bour et al. combined elements of adaptive and
directional stimulation by using feedback obtained
with measurement of -band power from various
channels at different depths and directions using a
32 contact DBS lead. Despite a small sample, they
demonstrated that stimulation in the direction of high-
est -band activity in the range of 18.5–30 Hz was
best associated with achieving the clinical outcome
of reducing rigidity [17].
DISCUSSION
Control of stimulation intensity through titration
of current or voltage has been the mainstay of DBS
programming since its inception. However, this has
limitations due to adverse effects with increasing
stimulation, and the roles of altering other param-
eters for specific indications or to reduce adverse
effects are becoming clearer as the effects of alter-
native settings are explored. This has been the case
particularly for frequency modulation, with substan-
tial evidence for improvement in FOG and other axial
symptoms with the use of lower settings in the range
of 60–80 Hz [6, 9–11, 36]. The persistence of this
effect however, is not certain based on current data,
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with some suggestion that it may not be maintained
in the long term [12]. It is not clear whether this is due
to wearing off and loss of efficacy of stimulation or
natural disease progression counteracting the benefit
over time. Moreover, amongst the studies that demon-
strate an improvement in axial symptoms with lower
frequency settings, this seems to be the case for a sub-
set of patients; it has been observed that those who do
not have tremor-dominant PD and have symptoms of
gait dysfunction with high frequency stimulation are
more likely to benefit [12, 13]. It is also interesting
that Xie et al. demonstrated in a small randomised
trial that the effect extends specifically to swallowing
function, with a substantial reduction in aspiration
[10]. This important finding may broaden the appli-
cability of lower frequency stimulation to PD patients
treated with DBS who suffer from the wider range of
axial symptoms including dysphagia rather than just
those with gait dysfunction.
It is also worth noting that the use of UPDRS axial
and gait subscores in many studies to measure out-
comes may have resulted in diminished detection of
effect than if more sensitive tools such as rapid 360◦
turns and the addition of dual-tasking were used to
assess freezing of gait [43, 44]. The mechanism of
low frequency stimulation and its beneficial effect
on axial symptoms in selected patients is not clear.
One of the proposed explanations is spread of cur-
rent to neurons projecting to the pedunculopontine
nucleus (PPN) which is in 5 mm proximity to the
STN and has reciprocal connections with it, as low
frequency stimulation of this structure directly and in
combination with STN stimulation has been shown to
improve FOG [45–48]. Relatively greater reduction
in akinesia noted with lower frequency stimulation
has also been suggested as a possible mechanism for
improvement in FOG [6, 9, 12]. It has been pos-
tulated that the negative impact on gait with high
frequency settings may be due to a change in STN
function in advanced PD caused by direct high fre-
quency stimulation, particularly when combined with
high voltages, as this is likely to result in current dif-
fusion into surrounding structures [6]. The location
of contacts in the STN may also influence the effec-
tiveness of low frequency stimulation, with ventrally
located contacts being favourable as demonstrated by
Khoo and colleagues [9]. This may also be partly
responsible for the heterogeneity of data on the effec-
tiveness of low frequency stimulation, as many of the
studies that demonstrated a significant improvement
tended to have largely used ventrally located contacts
[6, 9]. It should also be noted that most studies that
failed to show at least an initial improvement with
low frequency stimulation in patients who had trou-
blesome axial symptoms used lower TEED values at
low frequency stimulation [7, 8].
While a reasonable amount of work has been done
on the use of alternative frequency settings, larger
prospective blinded trials with detailed gait assess-
ments and longer follow up periods are required to
confirm the benefit of low frequency settings for axial
symptoms in the long term, and further define phe-
notypic subsets of patients who may benefit most.
In contrast, there is a paucity of data on the use
of alternative pulse width settings, in part due to the
lack of availability of PWs shorter than 60 s until
relatively recently in DBS systems. Only selected
manufacturers are now producing devices with this
capability for use with new implants. The effect of
ultra-short PWs utilised by Reich and colleagues
using the Boston Scientific Vercise™ system is very
encouraging in demonstrating the potential for sig-
nificant increases in the therapeutic window with
this approach. This is thought to be mediated by
more selective action of stimulation on neural fibre
tracts responsible for relief of symptoms while avoid-
ing those such as corticospinal and corticobulbar
fibres that result in adverse effects. This has been
demonstrated previously by Groppa et al. in patients
with essential tremor, where using strength-duration
curves plotted using various PW values, the chronaxie
(measure of excitability of neural elements) calcu-
lated for suppression of tremor was shown to be
significantly different to that for induction of ataxia,
with values of 27s and 52s respectively. They con-
cluded that a stimulation PW closer to the chronaxie
of tremor suppression would provide a wider thera-
peutic window between tremor relief and induction of
side effects [49]. The same concept was used by Reich
et al. to derive a strength-duration plot model for
axons of different diameters, showing a divergence of
action potential thresholds at lower PWs [37]. While
the exact nature of the fibres responsible for rigid-
ity control is not known, the magnitude of effect on
the TW with short PW stimulation found in these
patients certainly merits further investigation. Larger
randomised blinded trials to confirm the effects on
pyramidal as well as other common adverse effects
of stimulation such as dysarthria and axial symptoms
need to be carried out, as this has the potential to have
a significant clinical impact on existing and new DBS
patients.
As has been stated earlier, in interpreting the clin-
ical effects of varying stimulation parameters based
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on the available data, one should bear in mind that
most of the reviewed studies do not systematically
include the effect of the exact location of elec-
trodes or contacts used in their analyses. Further
randomised blinded trials controlling for this vari-
able will improve comparability between subjects
and studies.
Newer techniques have added a further dimension
to programming using basic parameters by modula-
tion of stimulation in space and time using directional
and adaptive stimulation respectively. While still in
early stages, available data suggests not only a reduc-
tion in side effects, but significant improvements in
energy requirements in terms of therapeutic current
required. Short pulse width, adaptive stimulation and
directional steering all share the same goal of improv-
ing specificity of stimulation to appropriate neural
elements to achieve the above clinical effects. While
systems capable of directional stimulation and short
pulse width have been made commercially available
recently, technology is lagging behind in providing
devices capable of adaptive programming. Indeed, it
would be of interest to examine whether a synergistic
or cumulative effect resulting from combining all of
these programming techniques exists. However, two
decades on, the need for more robust data on the use
of simple parameters such as shorter pulse widths is
long overdue.
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